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AbstrAct
Introduction High rates of co-occurring depression 
are reported in autism spectrum disorder (ASD), a 
neurodevelopmental condition characterised by social 
communication impairments and repetitive behaviours. 
Cognitive-behavioural interventions adapted for ASD have 
been effective for anxiety problems. There have been 
evaluation studies of group cognitive-behavioural therapy 
for co-occurring depression, but no randomised trials 
investigating low-intensity psychological interventions as 
recommended in clinical guidelines for mild-moderate 
depression.
Methods and analysis A feasibility study comprising a 
randomised controlled trial (RCT) and nested qualitative 
evaluation is under way as preparation for a definitive 
RCT. Participants (n=70) will be randomised to Guided 
Self-Help: a low-intensity psychological intervention based 
on behavioural activation adapted for ASD or treatment as 
usual. Outcomes including depression symptoms, anxiety, 
social function and service use will be measured at 10, 
16 and 24 weeks postrandomisation and will be blind to 
group allocation for measures that are not  
self-administered. The analysis will aim to establish 
the rates of recruitment and retention for a larger-
scale RCT as well as the most appropriate measure of 
depression to serve as primary outcome. The qualitative 
study will purposively sample up to 24 participants from 
each treatment group to consider the acceptability and 
feasibility of the intervention and the trial design.
Ethics and dissemination Ethical approval has been 
received from WALES REC 3 (IRAS project ID: 191558) 
and the Health Research Authority with R&D approval 
from Avon and Wiltshire Mental Health Partnership 
and Northumberland, Tyne and Wear Foundation NHS 
Trusts. To our knowledge, this is the first study of a 
low-intensity intervention for depression in adults with 
autism. The results will inform the design of a definitive 
RCT. Dissemination will include peer-reviewed journal 
publications reporting the quantitative and qualitative 
research findings of the study and presentations at 
national and international conferences.
trial registration number ISRCTN54650760; Pre-results.
bAckground
Autism spectrum disorder (ASD) is a neuro-
developmental condition characterised by 
qualitative impairments in social communi-
cation and a pattern of restricted, repetitive 
behaviour, interests or activities.1 High rates 
of co-occurring mental health problems 
have been reported in studies of children2 
and adults3 with ASD. These include depres-
sion, a common mental disorder character-
ised by persistent low mood, feelings of guilt 
and low self-worth, an absence of positive 
affect and disturbances in sleep, appetite, 
concentration and energy levels. Depres-
sion is a debilitating mental health problem 
and has been estimated as the leading cause 
of loss of disability-adjusted life years due 
to mental health and substance use disor-
ders.4 The estimated point prevalence for 
a depressive episode for adults aged 16–74 
in the UK general population in 2000 was 
2.6%.5 To date, there have been no robust 
epidemiological studies of depression in 
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strengths and limitations of this study
 ► This trial is funded following a commissioned call 
and thus aims to fill a clearly perceived clinical 
research and service gap.
 ► Recruitment procedures ensure diagnostic validity 
of autism spectrum disorder (ASD) and depression.
 ► Conclusions about effectiveness or efficacy of the 
intervention are not possible.
 ► Inclusion of clinician as well as self-report measures 
of depression symptoms aims to overcome the 
documented difficulties with self-report of emotional 
states in ASD.
 ► Patient and public involvement in the development 
of the intervention.
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ASD, but studies of clinical and research samples have 
reported high rates. For example, a clinical study of 122 
autistic adults with ASD found that 53% met criteria for 
depression at some point in their lives.6 A recent system-
atic review reported rates of depression ranging from 
4% to 35% across seven studies of autistic adults without 
intellectual disability.7 Although sampling and measure-
ment methods may contribute to the lack of consistent 
findings across studies, there is some evidence to suggest 
that the prevalence of depression is notably higher in 
autistic adults than the general population.
The National Institute for Health and Care Excel-
lence (NICE) Clinical Guidelines 908 recommend a 
stepped-care model for the treatment of depression. 
Mild-moderate depression should be treated according 
to step 2 of the care pathway, that is, low-intensity 
psychosocial interventions, psychological interventions, 
medication and referral for further assessment and 
treatment. Low-intensity interventions aim to increase 
access to evidence-based psychological therapies. They 
are characterised by the provision of evidence-based 
information, delivered by a range of ‘technologies’ such 
as written materials or computerised protocols, and 
facilitated by a mental health worker without formal 
professional training or self-facilitated. Monitoring 
and review are also important. Low-intensity psycho-
logical interventions for depression as recommended 
by the clinical guidelines8 are individual guided self-
help based on the principles of cognitive-behavioural 
therapy (CBT) to include behavioural activation and 
problem-solving techniques, computerised CBT or a 
structured group physical activity programme.
CBT refers to a group of psychological interventions 
which combine behavioural, cognitive and affect-focused 
techniques to bring about a reduction in psychological 
distress and an improvement in associated functional 
impairment. Adaptations to the delivery and content of CBT 
are outlined in the clinical guidance for adults with autism.9 
Recent systematic reviews indicate that CBT can be effec-
tive in reducing anxiety problems in young people10 11 and 
adults with ASD12 if adapted. Meta-analysis of the studies of 
adapted CBT interventions for emotional disorders in chil-
dren and adults report small–medium effect sizes (g=0.24 
on self-report outcomes, g=0.66 on informant measures 
and g=0.73 on clinician rated outcomes).13
Despite the high rates of co-occurring depression and 
the success in evaluating the effectiveness of adapting 
CBT for anxiety problems, there is a paucity of system-
atic evidence for its usefulness in treating depression 
in ASD. There have been two randomised evaluations 
of group CBT for young people with ASD using wait-
list and cross-over trial designs14 15 with mixed findings 
reported in respect of changes on the primary outcome 
measures and relatively small sample sizes. An adult 
study16 reported a significant effect of time but not treat-
ment group on anxiety and depression measures when 
comparing a CBT intervention with mindfulness-based 
stress reduction both adapted for ASD. There are then 
suggestions that CBT adapted for ASD may be effec-
tive for adults with co-occurring depression, but to 
our knowledge, there have been no published clinical 
effectiveness studies of individual cognitive-behavioural 
interventions, including behavioural activation or of a 
low-intensity intervention.
Clinical trials aside, naturalistic treatment evaluations 
are less well described and reported. Thus, it is not known 
whether adults with ASD and co-occurring mild-moderate 
depression routinely access CBT interventions offered 
in primary care or experience less favourable treatment 
outcomes. It is known that the materials for low-intensity 
CBT for depression have not been specifically developed 
with this group in mind.
Aims
As part of a commissioned call by the National Institute 
for Health Research Health Technology Assessment, 
this was a feasibility study for a large-scale randomised 
controlled trial (RCT) that would determine the clinical 
and cost-effectiveness of a low-intensity intervention for 
co-occurring depression in adults with autism. The aims 
of the feasibility study were to:
 ► Develop a low-intensity intervention for depression 
adapted for ASD based on NICE recommendations 
and accompanying training materials to guide thera-
pists in supporting the intervention.
 ► Investigate the feasibility and patient and therapist 
acceptability of the low-intensity intervention.
 ► Estimate the rates of recruitment and retention for a 
large-scale RCT.
 ► Identify the most appropriate outcome measure for a 
large-scale RCT.
MEthods
trial design
The trial will comprise a single-blind, RCT, with a nested 
qualitative evaluation. Participants will be randomly 
assigned to one of two treatment arms, a low-intensity 
intervention, Guided Self-Help for depression adapted 
for adults with autism (GSH), or treatment as usual 
(TAU).
recruitment
Participants (n=70) will be recruited from Adult Autism 
Clinics (n=2) and research organisations for adults with 
ASD (n=2).
Inclusion criteria
 ► aged ≥18 years
 ► clinical diagnosis of ASD
 ► current depression as measured by Patient Health 
Questionnaire (PHQ-9) score ≥10.
Exclusion criteria
 ► participants who are non-English speaking
 ► participants with literacy levels such that the written 
materials are inaccessible
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 ► risk of suicide such that a low-intensity intervention is 
not in line with clinical need
 ► history of psychosis
 ► current alcohol/substance dependence
 ► untreated epilepsy
 ► attended >6 sessions of individual CBT during the 
previous 6 months.
Procedure
Clinicians in the NHS Adult Autism Clinics will introduce 
the study to potentially eligible participants.
Coordinators of the two research pathways will intro-
duce the study to potentially eligible participants by mail-
shot, inviting people to find out more about the study 
according to the research opportunity protocols and 
guidelines.
Potentially eligible participants who express an interest 
in the study will be invited to contact the research team to 
find out more. Eligibility screening according to the inclu-
sion and exclusion criteria will then be conducted over 
telephone. Participants meeting the inclusion/exclusion 
criteria will be invited to a meeting where eligibility will 
be confirmed using the Clinical Interview Schedule—
Revised (CIS-R),17 a standardised interview conducted by 
the researcher.
Fully informed, written consent to participate in the 
study will be sought. The researcher will ask participants 
to summarise in their own words what taking part in the 
study will involve, including enquiring about their under-
standing of the voluntary nature of the study.
Baseline assessment will be completed face to face for all 
consenting participants and include a number of self-re-
port measures of depression, anxiety, obsessive–compulsive 
symptoms, quality of life, social function, rumination, repet-
itive behaviours and a current use of services questionnaire 
(see the Measures section). A clinician-administered depres-
sion measure will also be completed, the Hamilton Rating 
Scale for Depression (HRSD).
A preferred communication and research contact 
strategy will be agreed with each individual at the outset 
of their participation in the study. As well as working with 
individual preferences, the aim is to minimise any reten-
tion issues occurring as a result of core characteristics of 
ASD. Individual preferences may involve carers or other 
family members, a sole reliance on electronic communi-
cation, repeated reminders etc.
randomisation
Eligible and consenting participants will be randomly 
allocated to GSH (n=35) or TAU (n=35) via a remote 
computerised randomisation service. Randomisation 
will be stratified by NHS regional centre (n=2), and 
minimised by depression severity (mild-moderate, ie, 
PHQ-9 scores between 10 and 15 or moderate-severe, 
ie, PHQ-9 scores between 16 and 27) and antidepres-
sant medication (currently taking/not taking). The trial 
manager will share details of the outcome of randomis-
ation with the individual participants according to their 
communication preferences within 48 hours and with the 
therapist. Follow-up measurement will be carried out by 
researchers who will remain blind to treatment allocation 
(see figure 1 for timeline of events).
randomised treatments
Guided Self-Help
The intervention is based on the principles of behavioural 
activation for depression, adapted for ASD and delivered 
as a low-intensity intervention.
The intervention will be delivered over 10 weeks. The 
first session (0) is a planning session to orient the partici-
pant to the nature of guided self-help and the therapist to 
the nature of the participant’s ASD. Individualised goals 
for treatment are formulated during this session. Sessions 
1–4 contain information and tasks to facilitate learning 
about the importance of links between situations, 
behaviour and feelings. Activity scheduling to increase 
opportunities for positive mood, in line with treatment 
goals, form the basis for sessions 5–8. Session materials 
are written with visual cues to enhance the accessibility 
of the text. A consistent session format is maintained 
throughout the treatment. Feedback and advice about 
the materials during development was obtained from 
two adults with ASD. They provided feedback about the 
clarity and acceptability of the written text, accompanying 
visual images, suggested homework tasks, the content of 
examples used to convey concepts, the visual layout and 
format of the written materials, and the amount of mate-
rial provided for each individual session. A focus group 
of adults with ASD was then asked to provide feedback 
on the final version of the planning session and the study 
information sheets.
Therapist ‘guides’ will facilitate the sessions, encour-
aging participants to review and reflect on the session 
materials, and plan homework tasks. Therapist guides 
will be unqualified psychologists with a foundation 
knowledge in CBT consistent with the knowledge and 
skills of low-intensity therapists. They will include assis-
tant psychologists and clinical psychologists in training. 
They will not ordinarily have the knowledge and 
training to deliver individual, formulation-driven CBT. 
Therapists will receive 15 hours of training in the inter-
vention and 1 hour minimum of clinical supervision on 
a weekly basis. Supervision will be delivered by qualified 
clinical psychologists who have developed the interven-
tion. It can be face to face or remote (via telephone/
Skype) and can be delivered on an individual or group 
basis. A therapist manual has been developed for the 
intervention.
The intervention will be delivered face to face, with 
sessions lasting up to 45 min. The exception is the initial 
planning session which can last up to 90 min to facilitate 
engagement. The intervention can be delivered by tele-
phone or Skype if it is otherwise inaccessible to a partici-
pant. However it is designed to be delivered face to face, 
with the latter sessions (5–8) amenable to delivery by tele-
phone if preferred. Participants who attend ≥5 sessions 
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Figure 1 Timeline of events. ASD, autism spectrum disorder; GSH, Guided Self-Help; TAU, treatment as usual.
will be considered to have received a minimally effective 
dose of treatment.
Sessions will not be audio or video recorded. Therapists 
will complete a session record at the end of each session 
listing the treatment components covered in the session, 
engagement with the session, ease of completion of the 
session tasks and extent to which any homework tasks 
were completed. This will allow post hoc evaluation of 
any logistical and pragmatic issues arising with the session 
materials. Progress with individual client treatment goals 
will be rated by the client on a scale of 0–10 in sessions 0, 
4 and 8.
Session by session measures will be completed, 
comprising the PHQ-9, General Anxiety Disorder Ques-
tionnaire (GAD-7), brief Positive and Negative Affect 
Scale and engagement with daily activities. This will simu-
late routine practice in low-intensity interventions where 
ongoing monitoring is an important element.
Treatment as usual
There will be no restrictions on the care that can be 
provided as TAU. Participants randomised to TAU will be 
provided with information about how to self-refer to local 
Improving Access to Psychological Therapies (IAPT) 
services. TAU may comprise no treatment, self or general 
practitioner (GP) referral to IAPT services, Adult Autism 
Clinic recommending GP referral to IAPT services, Adult 
Autism Clinic or GP referral to secondary mental health 
services and/or antidepressant medication. TAU will be 
carefully recorded in terms of the timing and nature of 
any intervention received.
Eligibility measure
CIS-R17: The CIS-R is a structured diagnostic interview 
which generates International Classification of Disease-10 
(ICD-10) psychiatric diagnoses. The CIS-R is a widely 
used, well-validated diagnostic instrument. The CIS-R was 
administered via a computerised questionnaire in this 
study to assess the inclusion and exclusion criteria along-
side the PHQ-9 score.
outcome measurement
Follow-up assessment will be conducted at 10, 16 and 24 
weeks postrandomisation (see table 1 for a full schedule 
of assessment measures by time point) and will be carried 
out by researchers blind to treatment allocation. One aim 
of the study is to identify the most appropriate outcome 
measure for a large-scale RCT, thus, it is not possible to 
specify the primary outcome measure of depression a 
priori. The feasibility of delivering the intervention over 
10 weeks will be evaluated. Thus it is not clear if 10 or 16 
weeks postrandomisation will represent the most effective 
point of outcome measurement, that is, if the majority 
of participants are unable to complete the intervention 
within 10 weeks.
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Table 1 Timing of outcome measurement
Measure Baseline
GSH group each 
session
10 weeks (end of 
intervention) 16 weeks 24 weeks
Demographics √
PHQ-9 √ √ √ √ √
CIS-R √
BDI √ √ √ √
GRID HAM-D √ √ √ √
GAD-7 √ √ √ √ √
OCI-R √ √ √ √
PANAS √ √ √ √ √
WSAS √ √ √ √ √
SF-12 √ √ √ √
EQ-5D-5L √ √ √ √
Participant Global Rating of Change √ √
RBQ-2A √
RRQ √ √
Economic evaluation √ √ √
BDI, Beck Depression Inventory; CIS-R, Clinical Interview Schedule-Revised; EQ-5D-5L, EUROQOL 5 dimensions 5 
levels; GAD-7, General Anxiety Disorder Questionnaire; GRID-HAM-D, GRID Hamilton Rating Scale for Depression; 
GSH, guided self help; OCI-R, Obsessive Compulsive Inventory-Revised; PANAS, Positive and Negative Affect Schedule; 
PHQ-9, Patient Health Questionnaire; RBQ-2A, Repetitive Behaviours Questionnaire; RRQ, Rumination-Reflection 
Questionnaire; SF-12, 12-Item Short Form Health Survey; WSAS, Work and Social Adjustment Scale.
depression measures
PHQ-918: The PHQ-9 is a nine-item self-report measure 
of depression, which is commonly used in primary care 
settings. The PHQ-9 has been found to be reliable (Cron-
bach’s α=0.84–0.93), valid and sensitive to change in the 
general population.19 To the authors’ knowledge the 
psychometric properties of the scale have not been inves-
tigated with the autistic population.
Beck Depression Inventory-II (BDI-II)20: The BDI-II is a 
widely used, 21-item self-report measure of depression. 
The BDI-II has been found to be reliable (Cronbach’s 
α=0. 92) for outpatients.20 A validation study of 50 young 
people with ASD21 reported good internal consistency on 
the BDI-II (Cronbach’s α=0.90).
GRID-Hamilton Rating Scale for Depression (GRID-
HAMD-17)22: The GRID-HAMD is a version of the HRSD.23 
It is a 17-item clinician-administered interview which has 
been found to be reliable and valid in the general popu-
lation22 but to our knowledge has not been investigated 
in the autistic population. GRID-HAMD interviews will 
be audio recorded with participant consent. Record-
ings will be independently rated by a second rater for all 
items (excluding items 8 and 9 which require face-to-face 
assessment, ie, observation of psychomotor retardation 
and agitation) to establish reliability of each assessor. This 
will be done for the first six interviews conducted by each 
assessor. To establish reliability across the study, a random 
sample (20%) of GRID-HAMD recordings will be inde-
pendently rated.
Participant Global Rating of Change: Participants are 
asked to rate whether their depression is better, worse 
or much the same on a five-point scale at 16-week and 
24-week follow-up.
other measures
GAD-724: The GAD-7 is a seven-item self-report measure of 
anxiety. The scale has been found to be reliable and valid 
in the typically developing population24 (Cronbach’s 
α=0.92). However the psychometric properties for use 
with autistic individuals are not known.
Positive and Negative Affect Schedule (PANAS)25: The 
PANAS is a 20-item self-report scale of positive and nega-
tive affect. The scale has been found to be reliable with a 
Cronbach’s α of 0.89 for the positive affect scale and 0.85 
for the negative affect scale25 but has not been used with 
autistic individuals.
Obsessive–Compulsive Inventory—Revised (OCI-R)26: The 
OCI-R is an 18-item self-report measure of the symptoms 
of obsessive–compulsive disorder, with items such as ‘I 
feel I have to repeat certain numbers’, which are scored 
on a five-point Likert scale (0–4), indicating increasing 
frequency. The scale has been found to be reliable and 
valid.26 The OCI-R has been found to have good psycho-
metric properties in a sample of 225 autistic people.27
Work and Social Adjustment Scale (WSAS)28: The WSAS is 
a five-item self-report measure of impaired functioning 
which has been found to be reliable (Cronbach’s α=0.7–
0.94) and valid in typically developing individuals. It has 
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been used with autism populations, but its psychometric 
properties have not been assessed.
EQ-5D-5L29: The EQ-5D-5L is a five-item self-report 
measure of health, with items measured on a five-point 
Likert scale (1–5) indicating severity. It has been found 
to be reliable and valid in the typically developing 
population.30
12-Item Short Form Health Survey (SF-12)31: The SF-12 is a 
12-item self-report measure of physical and mental health. 
It has been found to be a reliable and valid measure 
among people with severe mental health problems,32 but 
psychometric properties for autistic populations are not 
available.
The Repetitive Behaviours Questionnaire (RBQ-2A)33: The 
RBQ-2A is a 20-item self-report measure of repetitive 
behaviours. It has been found to have good internal 
consistency, with Cronbach’s α between 0.73 and 0.83, and 
autistic people score significantly higher on the measure 
than typically developing individuals, suggesting that it is 
a valid measure of autism-specific repetitive behaviours.
The Rumination–Reflection Questionnaire (RRQ)34: The 
RRQ is a 12-item self-report questionnaire, comprising 
two subscales; rumination and reflection. The measure 
has good psychometric properties, and the rumination 
scale has a Cronbach’s α of 0.90, and the reflection 
scale 0.91.
Economic evaluation: We will pilot the feasibility of data 
collection on statutory health and voluntary service use 
using a questionnaire collecting information on: use of 
other primary and community care services (NHS Direct, 
attendances at walk-in centres, use of community health-
care services); secondary care related to mental health 
(number of outpatient visits, type of clinic and reason 
for visit; inpatient stays, length of stay and reason); use of 
social services and disability payments received; personal 
costs related to mental health (expenditure on over-the-
counter medication, expenditure on prescriptions, travel 
costs associated with healthcare visits, loss of earnings, 
out of pocket expenditure on other services, eg, private 
counselling or complementary or alternative therapies, 
child care and domestic help); time off work and unpaid 
activities. We will also access GP records to provide infor-
mation on: number of primary care consultations, by type 
for example, face-to-face, telephone etc, and who seen 
and prescribed medication.
statistical analysis
We will be following the recently published extension to 
Consolidated Standards of Reporting Trials (CONSORT)35 
when reporting the results of this feasibility trial. As this 
is a feasibility study there is no formal sample size calcula-
tion. Seventy participants were considered a large enough 
sample to consider the practicalities of recruitment and 
delivering the intervention.
For this feasibility study, we will calculate and present in 
a CONSORT flow chart:
1. the proportion of adults with ASD consenting to the 
study;
2. the proportion completing the baseline assessment 
and entering the randomised phase;
3. for those in the intervention group, the number of 
guided self-help sessions attended and the proportion 
completing five or more sessions;
4. the proportion completing follow-up assessments at 
10, 16 and 24 weeks postrandomisation.
We will explore the sensitivity to change of the various 
self-reported measures of depression in comparison with 
the GRID-HAMD (clinician-rated assessment of depression) 
in order to identify the most appropriate outcome meas-
ures for the main trial. We will also compare the contin-
uous scores on the depression outcome measures between 
groups. The SD of the chosen primary outcome will inform 
the sample size calculation for the large-scale RCT.
We will evaluate the service use and economical eval-
uation questionnaire by examining the rates of comple-
tion across individual questions. We will compare the 
information provided by participants about primary and 
secondary care health service use with information gath-
ered from GP and secondary care records.
Qualitative study
In-depth interviews will be conducted with participants 
(from both arms of the trial) 10 weeks after randomisa-
tion (after 10 week outcome measurement is complete). 
These interviews will consider and compare views and 
experiences of the trial and the acceptability of the 
guided self-help intervention. All therapists delivering 
the intervention will also be interviewed towards the end 
of the trial to illuminate the perceived effectiveness and 
acceptability of treatments and explore any barriers to its 
uptake outside of the trial.
Purposive sampling will select interviewees in order 
to attempt to capture maximum variation in views and 
experiences in order that they adequately reflect those 
of a range of participants. All participants in the trial 
will be asked if they are willing to be contacted about 
taking part in a qualitative interview at the time of trial 
consent. From participants who indicate that they are 
willing to be contacted, a purposive sample will be 
drawn in relation to (1) the trial site, (2) arm of the 
trial and (3) sociodemographic variables such as age, 
gender, ethnicity and socioeconomic status (with partic-
ipants being selected from areas of high and low social–
economic deprivation, based on Index of Multiple 
Deprivation (IMD 2007) score.36 Interviews will be anal-
ysed in batches, and sampling will continue until no new 
themes are emerging from the interviews. This is likely 
to include up to 24 participants as well as two to three 
therapist interviews.
All interviews will be conducted by telephone or 
face-to-face in a location of the participants’ choice. At 
interview, a flexible topic guide will be used to ensure 
primary issues are covered during all interviews, but without 
dictating data collection, allowing participants to intro-
duce unanticipated issues. Interviews are expected to last 
between 45–60 min. With informed consent, interviews will 
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be recorded using a digital voice recorder, transcribed and 
anonymised.
Interview transcripts will be checked for accuracy and then 
imported into NVivo10 qualitative data analysis software,37 
to aid management and indexing of data. Thematic anal-
ysis38 using a data-driven inductive approach39 will be used to 
scrutinise the data in order to identify and analyse patterns 
and themes of particular salience for participants and 
across the dataset using constant comparison techniques.40 
Analysis will begin shortly after data collection starts, will 
be ongoing and iterative. Analysis will inform further data 
collection; for instance, analytical insights from data gath-
ered in earlier interviews will help identify any changes that 
need to be made to the topic guide during later interviews. 
Transcripts from the participants and therapists’ interviews 
will be analysed separately, with coding frames being devel-
oped for each. A subset of transcripts will be independently 
double-coded by other members of the research team and 
compared. Discrepancies will be discussed and resolved to 
achieve a coding consensus.
Monitoring and adverse events
Adverse events and risk standardised operating proce-
dures have been developed and will be followed by all 
researchers and therapists working on the trial. Adverse 
events are defined as significant negative episodes, or 
significant deterioration in condition, which happen to 
participants during their time in the trial. These will be 
reported by research assistants and trial therapists to senior 
trial staff, who will ascertain whether these are thought to 
be linked to participation in the trial, and keep records 
of each event on an adverse events database. All serious 
adverse events of an unexpected and unrelated nature 
will be reported to the main Research Ethics Committee, 
the study Sponsor and Trial Steering Committee (TSC). 
Suicide risk will be monitored using the suicidality items 
on the PHQ-9 and BDI-II which are administered at base-
line, and 10, 16 and 24-week follow-up. If the participant 
states that they have had suicidal/self-harming thoughts 
every day in the last week (PHQ-9) or that they would 
like to kill themselves, or would kill themselves if they 
had chance (BDI-II), then a letter will be sent to their 
GP highlighting the individual’s risk. If the individual 
is considered to be high risk, a qualified clinician may 
also follow-up by offering information to the participant 
regarding local crisis teams, and call the GP to ensure the 
information is shared in a timely manner.
Independent oversight
A TSC and Data Monitoring and Ethics Committee will 
have independent oversight of the study, meeting at 6 
monthly intervals with quarterly reports of adverse and 
serious adverse events.
Potential limitations
The majority of participants in this study will receive a 
diagnosis of ASD during adulthood and thus may not be 
representative of all adults with ASD.
TAU may vary considerably by geographical region and 
service factors may act as a potential confound.
suMMAry
High rates of co-occurring depression, a debilitating 
mental health problem, have been reported in adults 
with ASD.6 There has been little research to date about 
the usefulness of adapted CBT for depression in autism 
or about routine service outcomes for this group. This 
feasibility study aims to develop a low-intensity interven-
tion for depression for adults with autism based on cogni-
tive-behavioural principles and accompanying therapist 
guidelines and training. The study design will enable 
the research team to consider the feasibility of carrying 
out a large-scale RCT to consider the effectiveness of the 
intervention, including specifying the most appropriate 
primary outcome measure. The nested qualitative study 
will address issues of patient and therapist acceptability of 
the intervention.
trial status
The pilot RCT is currently open to recruitment and the 
last participant is scheduled to be randomised by the end 
of September 2017. The trial will run until the end of 
April 2018.
The full trial protocol can be accessed at NIHR Jour-
nals Library (https://www. journalslibrary. nihr. ac. uk/ 
programmes/ hta/ 144302#/).
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